Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will...

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will...

IOVA : 9.87 (-0.20%)
JPM : 105.47 (-0.21%)
Iovance Biotherapeutics to Participate at November Investor Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Company to Host Conference Call at 4:30pm ET Today

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

-- 38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully treated with a prior PD-1 blocking antibody

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will host...

IOVA : 9.87 (-0.20%)
How This Underfollowed $6 Biotech Could Be Worth $10

The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous...

IOVA : 9.87 (-0.20%)
ORGS : 5.20 (+0.78%)
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

Offering Includes Exercise in Full of the Underwriter's Option to Purchase an Additional 3.3 Million Shares of Common Stock

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company's Clinical Program

--FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor...

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

- Company to Host Conference Call at 4:30pm ET Today -

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report...

IOVA : 9.87 (-0.20%)
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 9.87 (-0.20%)
DB : 8.66 (-0.92%)
Technical Perspectives on Biotech Stocks -- Intrexon, Iovance Biotherapeutics, Jaguar Health, and Jazz Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on XON, IOVA, JAGX, and JAZZ which can be accessed for free by signing up to www.wallstequities.com/registration....

IOVA : 9.87 (-0.20%)
JAZZ : 125.21 (-1.24%)
XON : 7.92 (-0.38%)
JAGX : 0.23 (unch)
Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enanta Pharmaceuticals, Inc....

SFBS : 36.05 (-0.74%)
IOVA : 9.87 (-0.20%)
ENTA : 98.02 (-2.42%)
AKCA : 25.45 (-3.05%)
PGC : 29.46 (-0.34%)
ALOG : 83.95 (unch)
LBIO : 6.95 (-2.80%)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX +0.04
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar